Fate Therapeutics
FATE
#9044
Rank
S$0.16 B
Marketcap
S$1.40
Share price
-1.82%
Change (1 day)
-56.07%
Change (1 year)

Fate Therapeutics (FATE) - Cash on Hand

Cash on Hand as of September 2025 : S$0.27 Billion

According to Fate Therapeutics 's latest financial reports the company has S$0.27 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Fate Therapeutics - Cash on Hand chart (from 2012 to 2025)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31S$0.37 B-8.87%
2023-12-31S$0.41 B-28.82%
2022-12-31S$0.58 B-29.77%
2021-12-31S$0.83 B30.33%
2020-12-31S$0.63 B114.01%
2019-12-31S$0.29 B8.71%
2018-12-31S$0.27 B103.38%
2017-12-31S$0.13 B1.28%
2016-12-31S$0.13 B45.42%
2015-12-31S$91.67 M41.3%
2014-12-31S$64.87 M-5.23%
2013-12-31S$68.46 M516.09%
2012-12-31S$11.11 M34.35%
2011-12-31S$8.27 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Sarepta Therapeutics
SRPT
S$1.10 B 295.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Becton Dickinson
BDX
S$0.98 B 251.40%๐Ÿ‡บ๐Ÿ‡ธ USA
PTC Therapeutics
PTCT
S$2.18 B 683.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Avidity Biosciences
RNA
S$2.43 B 770.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
S$1.44 B 417.49%๐Ÿ‡บ๐Ÿ‡ธ USA